Tomorrow’s Medicine: Curing One Patient at a Time

In biomanufacturing, business, Generis, generis group, manufacturing, mfg, value chain by Generis0 Comments

You know that tomorrow’s medicine is personalized. With more than 8,100 active cell therapy studies and 1,300 active gene therapy studies underway now, you’re changing the way patients will be treated.

To achieve the best clinical outcomes, the living cells and biological samples you develop or treat must be transported to patients on time and under the most rigorous product and stability specification. Anything less than perfect is unacceptable.

The World Courier eBook below highlights the logistics challenges of gene and cell therapies. Download the full eBook below for more information! 

CGT_book_thumbnail[1].jpg

Leave a Reply